Vedder Thinking | News Vedder Price Counsels Protein Sciences Corporation on Obtaining Regulatory Exclusivity of Flublok®
June 4, 2015
Members of the Vedder Price Intellectual Property group filed and prosecuted Protein Sciences Corporation's patent portfolio on influenza vaccines, which includes Flublok®, a recently FDA-approved recombinant influenza vaccine. Flublok® is made by using modern DNA and cell culture technology to produce just the protective ingredients needed for the influenza vaccination without growing the influenza virus. Vedder Price attorneys successfully obtained a five-year patent term extension and a twelve- year FDA biologics exclusivity period for Flublok®.
Click here to view the Protein Sciences Corporation’s press release for more information.